Tagged with Investment

pharma Lourdes de Cárdenas, vice president of Stryker’s Latin American operations, explains how she has revamped the Puerto Rican facility to become a more efficient operation and their current vision to continually improve and exceed expectations as a critical supplier of disposables for the company. How do you find the Stryker…

pharma The country president for South Africa & Sub-Saharan Africa at AstraZeneca reveals why AstraZeneca sees Africa as the next frontier within the pharmaceutical industry, how their Research Trust looks to contribute to academic advancement on the continent, with a focus on non-communicable diseases, and how their Healthy Heart Africa program…

pharma From humble beginnings to one of the largest companies in Mauritius; the CEO of Aspen Global Incorporated Mauritius explains the significance of the Mauritian holding for one of the fastest growing companies in the pharmaceutical sector. He illustrates how Mauritius has provided the right conditions for this success and sets…

pharma Groupe Socota launched the Mauritius’ first BioPark, Socota Phoenicia. The group’s chairman and CEO discusses why investing in life sciences is the right business decision for both his company and Mauritius. As a Madagascan conglomerate with no track record in life sciences, how did you make the decision to start…

pharma The general manager of Astellas France and president of LEEM, the French Pharmaceutical Companies Association, reveals how the pharmaceutical industry worldwide has to take into account what is a fair price for innovation, the sum of a value price, based on what you are providing for the health of a…

Pharma The phasing out of fiscal incentives in 2006 has impacted the Puerto Rican economy as well as the life science arena. The president of DDD Group, a company offering fully integrated services for capital project delivery, discusses the new challenges the industry is facing in terms of construction as well…

Pharma OrganoPlates™ serve as a highly useable platform for 3D cell cultures, are completely compatible with existing lab equipment, and can be used to develop true ‘organ-on-a-chip’ models. Co-founders of the developer and manufacturer, Mimetas, discuss the impact this product is already having on the drug development process, and its potential…

Pharma Yves Bur reveals how the motivation behind his political engagement has been to raise awareness around the importance of improving the social security system. Bur also explains why having a real public health policy is another way of combatting the increase in health spending, and how France needs to reach…

Pharma Skanska Puerto Rico’s Ramon Navia discusses the challenges the sector has faced in recent years and how Skanska has adapted its services portfolio to better cater to local clients’ needs. Skanska provides world-class construction management services to the life science industry.  What differentiates Skanska from other competitors and makes the group the…

Turkey Multinational R&D investment in Turkey, particularly investment in clinical trials, has been quite limited relative to the size of the Turkish pharmaceutical market. Turkish R&D spending amounted to just 0.95 percent of GDP last year, but the country plans to reach three percent of GDP by 2023. Multinational R&D investment…

Turkey In the coming years, Turkey plans to prioritize R&D initiatives, health studies and medical innovation: that’s the core message Minister of Health Mehmet Müezzinoğlu gave PharmaBoardroom. This is the beginning of a new era for healthcare in Turkey. The twenty-first century has already been a period of change in the…

Chiesi Chiesi is preparing to market two first in class products: the first approved stem cell treatment in Europe, and the first approved gene-therapy, developed in the Netherlands by partner UniQure. General Manager Nether Maurits Huigen discusses the challenges his affiliate is facing to bringing these pioneering products to market, along…